INTRODUCTION
Although recent advances in the management of acute myocardial infarction (AMI), including primary percutaneous coronary intervention strategies and evidence-based therapies, have resulted in a substantial decline in mortality, the number of post-AMI patients who survive an AMI but develop ischemic HF is increasing worldwide 1 . Therefore, the identification of biomarkers that can predict risk of HF development in post-AMI patients is needed for optimizing management and treatment strategies. To date, several types of biomarkers, such as N-terminal pro-brain natriuretic peptide and cardiac troponin T, have been shown to predict cardiovascular events after AMI; however, it remains inconclusive whether these biomarkers can predict future HF in post-AMI patients 2 .
MicroRNAs are small endogenous non-coding RNAs that regulate gene expression post-transcriptionally. Recently, various cell types were found to release microRNAs in membrane-bound vesicles termed exosomes, which circulate stably in the bloodstream [3] [4] [5] . Although the physiological significance of circulating microRNAs is not fully understood, they have attracted attention as potential diagnostic and prognostic biomarkers for various diseases, particularly cancer 3, 4 .
With respect to cardiovascular disease, a number of cardiac microRNAs, including miR-1, miR-133a, and miR-208a, have been detected in the serum in the acute phase of AMI and thus represent potentially useful diagnostic markers for AMI 5, 6 . However, these microRNAs are most likely released from necrotic heart tissue into the blood directly and are not encapsulated within exosomes, and therefore have short half-lives. For this reason, these cardiac microRNAs are unlikely to be predictive of future HF development in post-AMI patients 6 .
The aim of the present study was to identify circulating microRNAs that can serve as predictors of HF development in patients who survive the acute stage of AMI.
METHODS
We retrospectively analyzed the records of patients registered in the Osaka Acute Coronary Insufficiency Study, which has been described elsewhere
RESULTS
To identify microRNAs with altered expression in accordance with HF development after the convalescent stage of AMI, we initially compared the expression level of individual microRNAs in sera collected a median of 18 days after AMI onset using a high-throughput array between HF and control groups (n=7, respectively). Among 377 microRNAs, the expression levels of 14 microRNAs were found to significantly differ between the two groups when U6 snRNA, miR-766, or let-7d was used as an internal control (Online Table I ). The serum levels of the 14 microRNAs were further examined in a second screening. Two of the microRNAs, miR-485-3p and miR-518d-3p, were below the limit of detection of the assay. However, the expression level of miR-192 was significantly up-regulated in the HF group, whereas those of the remaining 11 microRNAs were comparable between the two groups ( Figure 1A and Online Figure I ).
Because miR-192 is reported to be p53 responsive, the levels of two p53-responsive microRNAs, miR-194 and miR-34a 8, 9 , were also measured. As anticipated, the serum levels of miR-194 and miR-34a were also up-regulated in the AMI patients who developed ischemic HF ( Figure   1B ). Furthermore, the miR-192, miR-194, and miR-34a expression levels were significantly correlated with one another, suggesting that the three microRNAs were coordinately up-regulated in a single cascade, such as the p53 signaling pathway. In particular, a high correlation (r=0.86) was detected between miR-194 and miR-34a (Online Figure II) . We also examined the serum levels of miR-208 and miR-499, which are candidate markers for severe myocardial damage and necrosis 10 , but neither microRNA was detected in the serum of either the HF or control groups.
To investigate whether miR-192, miR-194, and miR-34a were released into the serum within exosomes or had directly leaked from necrotic heart tissue, we separated collected serum into exosome and supernatant fractions. Western blot analysis against CD63, an exosome marker protein, confirmed the purity of the two fractions ( Figure 2A ). The levels of the three microRNAs were then quantified in each fraction, demonstrating that all three microRNAs were highly enriched in the exosome fraction ( Figure 2B ). We further compared the expression levels of these microRNAs in each fraction between the HF and control groups. Although no significant differences were detected in the supernatant fraction, the expression levels of miR-192 and miR-194 in the exosome fraction of the HF group were significantly higher than those of the control group ( Figure 2C) . A similar tendency was also observed for miR-34a, suggesting that the three microRNAs were mainly released into the serum within exosomes. Using cultured myoblasts derived from embryonic rat heart, we confirmed that both intracellular and extracellular levels of miR-192, miR-194, and miR-34a were increased following p53 activation, and that knockdown of these three microRNA increased cell viability, whereas transfer of extracellular microRNAs via the culture media decreased cell viability of myoblasts ( Figure 3 Table III ). This finding suggested that the serum levels of these p53-responsive microRNAs could predict left ventricular remodeling after the convalescent stage of AMI.
DISCUSSION
In this study, we demonstrated that serum levels of the microRNAs, miR-192, miR-194, and miR-34a are up-regulated as early as a median of 18 days after AMI onset in patients who survived AMI but developed HF within one year. Furthermore, circulating miR-194 and miR-34a levels in the convalescent stage of AMI were associated with LVDd. Thus, these p53-responsive microRNAs may be useful for stratifying the risk of future ischemic HF events and cardiac remodeling in post-AMI patients.
As the expression levels of the three identified microRNAs were well correlated with each other, it is conceivable that their expression was coordinately up-regulated in a single cascade. One of the most likely candidates for an inducer of this coordinated expression is the tumor suppressor p53, because all three microRNAs are reported to be induced by the direct binding of p53 to the promoter regions of the corresponding genes 8, 9 . In particular, it was recently demonstrated that miR-34a is induced in a p53-dependent manner, and that cardiomyocyte apoptosis can be suppressed through the blockade of miR-34a processing in a mouse model of AMI
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. Indeed, we confirmed that these three microRNAs are induced by p53 activation in cultured myoblasts and are subsequently released from cells. Furthermore, transfer of these extracellular microRNAs accelerated cell death. Taken together with our recent finding that p53 accumulation in the myocardium in response to pressure overload or after MI plays an essential role in HF progression in mice 12, 13 , our present results suggest that activation of p53 and the increased expression of the p53-responsive microRNAs miR-192, miR-194, and miR-34a are likely involved in the pathogenesis of HF after AMI. However, it remains undetermined whether circulating p53-responsive microRNAs were derived from infarct or ischemic heart tissues.
Interestingly, circulating miR-208b and miR-499, which are both reported to reflect severe myocardial damage or necrosis 10 , were not detected in the serum of either in HF or control patients in the present study. Thus, detection of p53-responsive microRNAs may have reflected ongoing myocardial damage associated with development of future HF, which was qualitatively different from necrosis.
It was recently reported that miR-34 family members are up-regulated in the heart in response to stress, including AMI, and that systemic injection of miR-34 antimiR significantly attenuated cardiac remodeling and dysfunction in a mouse AMI model 14 . Accordingly, modification of the p53 pathway using microRNA-based technologies may be a novel therapeutic approach to prevent ischemic HF in post-AMI patients, particularly for those with increased levels of circulating p53-responsive microRNAs.
In conclusion, we identified three p53-responsive microRNAs that were up-regulated in the 
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Novelty and Significance
What Is Known?  A number of patients survive acute myocardial infarction (AMI), but develop chronic ischemic heart failure (HF).
 MicroRNAs are non-coding small RNAs that are released from various cell types and circulate in the bloodstream.
 Accumulation of p53, a multifunctional protein, after AMI plays an essential role in HF development in mice. Although measurements of circulating microRNAs have been reported to be useful for the diagnosis of AMI and HF, it is not clear whether mRNA levels are reliable predictors of ischemic HF that develops after AMI. We found that three p53-responsive microRNAs are up-regulated during the early convalescent stage of AMI in the sera of patients who developed HF within one year after discharge.
What New Information Does This
Moreover, serum levels of these microRNAs were positively correlated with LVDd one year after AMI.
These findings suggest that circulating p53-responsive microRNAs may be clinically useful as predictive indicators of HF in post-AMI patients. patients, 218 were hospitalized for HF during a median of 1069 days after survival discharge. In the first screening phase, we randomly selected 7 patients who developed HF within one year after discharge (HF group) and an additional 7 patients who did not experience any cardiovascular events throughout a 2-year follow-up period (control group), using propensity score-based matching of age, sex, diabetes mellitus, hypertension, dyslipidemia, smoking, previous MI, Killip class >II at AMI onset , infarction size, reperfusion therapy rates, and medication at the time of serum collection to adjust for potential baseline differences between the two groups. In the second screening, we increased the number of patients (HF group; n = 21, control group; n = 65) and again matched the backgrounds of each group (Online Table II ) to validate the results obtained in the first screening.
Serum collection
Fasting blood samples were collected into serum separator tubes in the convalescent phase of AMI (median; 18 days after AMI onset) and were then incubated at 4°C for 4 h. After centrifugation at
Exosome isolation
Serum exosomes were isolated using ExoQuick Exosome Precipitation Solution (System Biosciences, Mountain View, CA) according to the manufacturer's protocol with a minor modification. Briefly, 250
µl of serum was centrifuged at 5,700 rpm for 15 min at 4°C to remove cell debris, and the resulting supernatant was then transferred to new sterile tubes, to which 63 µl of ExoQuick Exosome Precipitation Solution was added. After overnight incubation at 4°C, the tubes were centrifuged at 4,000 rpm for 30 min at 4°C to obtain the exosome-containing pellet, which was then resuspended in 25 µl phosphate buffered saline (exosome fraction). Half of the supernatant fraction (~150 µl) and the exosome fraction were stored at -20°C until use.
When exosomes were extracted from culture media, we treated culture media with RNase cocktail (Life Technologies Co., Carlsbad, CA) at a final concentration of 5 U/mL RNase A and 200 U/mL RNase T1, then incubated them at 37°C for 30 min. Then, 500 µl of culture media was centrifuged at 5,700 rpm for 15 min at 4°C to remove cell debris, and the resulting supernatant was then transferred to new sterile tubes, to which 500 µl of ExoQuick Exosome Precipitation Solution was added. After overnight incubation at 4°C, the tubes were centrifuged at 4,000 rpm for 30 min at 4°C to obtain the exosome-containing pellet, which was then resuspended in 25 µl phosphate buffered saline (exosome fraction) as previously described 4 .
RNA isolation
Total RNA in the serum was isolated using a mirVana PARIS kit (Life Technologies Co.) according to the manufacturer's protocol. Briefly, 1 ml of the serum was thawed on ice and lysed with an equal volume of 2x Denaturing Solution for 5 min. After an equal volume of acid phenol chloroform was added, the sample tube was centrifuged at 12,000 rpm for 5 min at 4°C. The aqueous phase was carefully transferred to a new tube, and 1.25 volumes of 100% ethanol were then added. The sample was then passed through a mirVana PARIS column followed by washing three times with 75% ethanol, and total RNA was then eluted in 100 µl of preheated (95°C) nuclease-free water and stored at -80°C until use.
Total RNAs in the serum exosome and supernatant fractions were extracted using ISOGEN II (Nippon Gene Co., Tokyo, Japan) according to the manufacturer's instructions. Briefly, the supernatant (~150 µl) and exosome solution (25 µl) were diluted to 400 µl with nuclease-free water and then lysed with 1 ml of ISOGEN II at room temperature for 15 min. After centrifugation at 12,000 rpm for 15 min at 4°C, 1 ml of the supernatant was transferred to a new tube and mixed with 1 ml isopropanol and 7.5 µg/ml glycogen. After incubation on ice for 30 min, the sample tubes were centrifuged at 12,000 rpm for 15 min at 4°C, and then washed twice with 500 µl 75% ethanol. Finally, the isolated RNAs from the exosome and supernatant fractions were dissolved in 25 µl and 12.5 µl of RNase free water, respectively, and stored at -80°C until use. When total RNAs were extracted from cell culture media using ISOGEN II, a total of 2.5 fmol of synthetic C. elegans microRNA-39 (Qiagen, Hilden, Germany) was added to media as an external standard as previously described 4 .
Reverse transcription (RT) and preamplification
RT and preamplification steps were performed using a TaqMan primers, and 7.5 µl nuclease-free water, and was then preamplified for 10 min at 95°C, for 2 min at 55°C and for 2 min at 72°C, and 12 cycles for 15 s at 95°C and for 4 min at 60°C.
MicroRNA profiling
Expression of 377 microRNAs was screened using a TaqMan solution (Life Technologies Co.), 100 IU/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin B (Life Technologies Co.). Cells were grown at 37°C in a 5% CO 2 humidified incubator.
For p53 activation, 1.0 µM of doxorubicin (Sigma-Aldrich) was added to culture media after 48h of serum removal as previously described 6 .
Knockdown of microRNAs in cardiac myoblasts
The 
Establishment of stable HEK293-derived stable cell lines that over-expressed microRNAs
To generate expression constructs for pri-miR-192, pri-miR-194 and pri-miR-34a tagged with ZsGreen1, a fragment of human chromosomal DNA encompassing the region transcribed to yield each pri-miRNA was amplified using human genomic DNA (Novagen, Darmstadt, Germany) as a template and then inserted into the pmR-ZsGreen1 vector (Clontech, Mountain View, CA) as previously 
Cell viability and caspase activity assays
Cell viability and caspase 3/7 activity were analyzed with CellTiter-Fluor Cell Viability Assay and Caspase-Glo 3/7 Assay kits (Promega) according to the manufacturer's instruction. In brief, 20 µl of CellTiter-Fluor Reagent was added to cells, and then incubated for 30 minutes at 37°C by orbital shaking. For caspase activity assay, an equal volume of Caspase-Glo 3/7 Reagent was further added to each well, and then incubated for 30 minutes at room temperature. Cell viability was assessed by using a fluorometer (400 nm/505 nm; SH-9000Lab, CORONA ELECTRIC Co.), and Caspase-3/7 activity was assessed by a luminometer (SH-9000Lab, CORONA ELECTRIC Co.).
Co-culture experiments
Co-culture experiments were performed as previously described 8 using well inserts for 24-well plates with a 0.4 µm pore sized filter (Thin Cert TM ) (Greiner, Frickenhausen, Germany). H9c2 cells were seeded into the lower well and cultured for 24 hours prior to the co-culture experiments. Then, either HEK293 or HEK293-derived stable cell lines that over-expressed microRNAs were seeded into the upper well. After incubation for 24 hours, 0.01 µM of doxorubicin was added to activate p53.
Statistical analysis
Variables are displayed as the mean ± standard deviation (SD) and qualitative data are presented as percentages. Patient characteristics were assessed using the Student's t test, and chi-square test.
Results were analyzed by the Mann-Whitney U test or Student's t test. Correlations were tested using
Pearson's correlation coefficient, and r values are presented as Pearson product-moment correlation coefficients. All P values are two-sided and statistical significance was set as P<0.05 (*), P<0.01 (**) or P<0.001 (***). All statistical analyses were performed using SPSS version 11.0 (SPSS Japan, Inc., Tokyo, Japan).
Online Figure I . Comparison of the serum expression of 11 out of 14 microRNAs selected in the first screening between the heart failure and control groups. Expression levels of 11 microRNAs in sera of the HF group (black bars, n=21) and control group (white bars, n=65) are displayed as the mean ± SEM after normalization to U6 snRNA, which was used as an internal control. No significant differences in expression were observed between the two groups. 
